Brokerages Split on Biocon; Targets Range from ₹326 to ₹495

📊

received mixed views from brokerages. DAM Capital Advisors Limited maintained a 'Buy' rating with a target price of ₹495, citing confidence in the company's biosimilars growth. In contrast, Bernstein retained an 'Underperform' rating with a target price of ₹326, highlighting concerns over leverage and execution.